Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 44 results for "sarabjit kour nangra"

Neutral rating on Cipla, Sun Pharma no game changer: Sarabjit ...

will add to the company but since the company is so big that such small approvals do not add significantly." In an interview with ET Now, Sarabjit Kour Nangra, VP - Research, Angel Broking, Pharma, shares his views on markets. Excerpts: ET Now: What is that ... Economic Times, 1 month ago

Infosys' topline a positive surprise; revenue growth commendable: Sarabjit Kour Nangra, Angel Broking

ne has positively surprised. 4.5% revenue growth QoQ is really commendable." In a chat with ET Now, Sarabjit Kour Nangra, Angel Broking, talks about Infosys' latest numbers. Excerpts: ET Now: Prima facie, Infosys' numbers look okay. What is your take? ...
 Economic Times2 months ago

IT majors poised for strong revenue growth

While currency depreciation is expected to boost the bottom lines of most IT majors, the same is expected to shave off revenue gro­wth for the seventh straight qua­r­ter. However, in constant currency terms, the firms are expected to post strong revenue ...
 The Financial Chronicle3 days ago IT majors witness sustantial growth in quarterly revenue  The Financial Chronicle2 months ago
Millennium Post

HCL Tech crashes 13% on revenue worries; m-cap down `17,449 cr

Shares of IT services firm HCL Technologies on Thursday fell by nearly 13 per cent , wiping out Rs 17,449 crore from its market valuation, after the company said it expects revenues for the September quarter to be "tepid". Consequently, shares of ...
 Millennium Post6 days ago HCL Tech dips 13%; mcap down by Rs 17,449 crore on revenue worries  DNA India1 week ago
Financial Express

HCL Tech nosedives 15% on weak revenue guidance

NEW DELHI: Shares of HCL Technologies (HCL Tech) plummeted nearly 15 per cent in Thursday's trade after the IT major lowered its dollar revenue guidance for the third quarter in a row. The Noida-based firm, whose financial year begins in July, believes its ...
 Economic Times1 week ago HCL Technologies shares nosedive 15% on weak Q1 outlook  Financial Express1 week ago HCL foresees poor revenue growth in Q1  Livemint.com1 week ago
SME Times

Sun Pharma's scrip down 3.42 pc on US FDA's quality concerns

Indian drug major Sun Pharmaceutical's scrip plunged 3.42 percent or 30.50 points on Monday, after the US Food and Drug Administration (FDA) rescinded its earlier approval for a drug launch. The US FDA revoked an approval issued in March to Sun ...
 SME Times1 week ago Sun Pharma, SPARC shares fall after US FDA revokes approval for drug  Livemint.com1 week ago Sun Pharmaceutical Industries Ltd Shares Flare Up on US FDA Nod for Dermatology Drug  MedIndia1 month ago Sun Pharma shares close 3% higher on Q1 earnings  Money Today1 month ago

Dr Reddy's jumps 5.5% on launch of new drug in the US

Hyderabad/Mumbai: Shares of Dr. Reddy's Laboratories Ltd gained as much as 6.3%, the most in four years, after the company said it has launched the generic version of AstraZeneca Plc's gastric acidity drug Nexium in the US. This is the ...
 Livemint.com1 week ago
Business Standard India

Lupin diabetes drug price up by 200% in US

Lupin has raised the price of its anti-diabetes drug in the US market by 200 per cent. The move could increase its product revenue to around $100 million, say analysts. Lupin sells a generic version of Fortamet (Metformin Hydrochloride) and competes ...
 Business Standard India2 weeks ago Lupin raises diabetes drug price by 200%  Business Standard India2 weeks ago

Riding the falling rupee

The depreciating rupee has been nightmarish for most sectors except information technology and pharma. The two net exporting sectors have been strengthening their bottomlines over the last few quarters. While most major IT players reported muted growth in ...
 The Financial Chronicle3 weeks ago

US Clears Infosys Of H1-B Visa Violation Charges

Infosys on Tuesday said that that the US department of labor had cleared the company of charges of visa violations. In June, the U.S. government had opened an investigation against two of the biggest Indian outsourcing companies—Infosys and TCS ...
 CXOtoday1 month ago H-1B Visa Violation: Infosys Gets Clean Chit from US  International Business Times India1 month ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - sarabjit kour nangra
Get updated on latest news & your favorite topics right in your inbox!
More     Less